NEW YORK (GenomeWeb News) – Quest Diagnostics subsidiary Focus Diagnostics has licensed non-exclusive, worldwide rights to Asuragen’s Armored RNA technology for use in molecular diagnostic products, the firms said today.
The Armored RNA technology was jointly developed by Austin, Texas-based Asuragen and reference lab Cenetron Diagnostics for the packaging of RNA or DNA in bacteriophage coat proteins for protection and stabilization. According to the firms, the technology armors the RNA standard against the hazards of nucleases in patient samples.
Asuragen will develop and supply reagents for Focus in its QSR-compliant manufacturing facility. Other terms of the agreement were not disclosed.
Asuragen is a spin off of RNAi technologies firm Ambion, which was acquired by Applied Biosystems at the end of 2005 for around $273 million.